These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9200944)

  • 1. [Manipulation of costimulatory pathways in autoimmune disease].
    Kaneko H; Nakajima A; Azuma M
    Nihon Rinsho; 1997 Jun; 55(6):1531-6. PubMed ID: 9200944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.
    Salomon B; Bluestone JA
    Annu Rev Immunol; 2001; 19():225-52. PubMed ID: 11244036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Costimulatory molecules in autoimmunity: role of CD28/CTLA4-CD80/CD86].
    Nakajima A; Azuma M
    Nihon Rinsho; 1997 Jun; 55(6):1419-24. PubMed ID: 9200926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
    McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
    Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
    Zhou T; Weaver C; Linsley PS; Mountz JD
    Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin.
    Mukherjee S; Maiti PK; Nandi D
    J Leukoc Biol; 2002 Nov; 72(5):921-31. PubMed ID: 12429713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells.
    Manzotti CN; Tipping H; Perry LC; Mead KI; Blair PJ; Zheng Y; Sansom DM
    Eur J Immunol; 2002 Oct; 32(10):2888-96. PubMed ID: 12355442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The B7-CD28 superfamily.
    Sharpe AH; Freeman GJ
    Nat Rev Immunol; 2002 Feb; 2(2):116-26. PubMed ID: 11910893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis.
    Quattrocchi E; Dallman MJ; Feldmann M
    Arthritis Rheum; 2000 Aug; 43(8):1688-97. PubMed ID: 10943858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins.
    van Wijk F; Nierkens S; de Jong W; Wehrens EJ; Boon L; van Kooten P; Knippels LM; Pieters R
    J Immunol; 2007 Jun; 178(11):6894-900. PubMed ID: 17513738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and functional significance of CTLA-4, a negative regulator of T cell activation.
    Kosmaczewska A; Ciszak L; Boćko D; Frydecka I
    Arch Immunol Ther Exp (Warsz); 2001; 49(1):39-46. PubMed ID: 11266089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4.
    Höllsberg P; Scholz C; Anderson DE; Greenfield EA; Kuchroo VK; Freeman GJ; Hafler DA
    J Immunol; 1997 Nov; 159(10):4799-805. PubMed ID: 9366404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT; Bluestone JA
    Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of CD80 and CD86 with CD28 and CTLA4.
    Ellis JH; Burden MN; Vinogradov DV; Linge C; Crowe JS
    J Immunol; 1996 Apr; 156(8):2700-9. PubMed ID: 8609386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manipulation of costimulatory pathways in autoimmune diseases.
    Nakajima A
    Mod Rheumatol; 2001 Sep; 11(3):184-91. PubMed ID: 24383724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival.
    Judge TA; Wu Z; Zheng XG; Sharpe AH; Sayegh MH; Turka LA
    J Immunol; 1999 Feb; 162(4):1947-51. PubMed ID: 9973463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis.
    Perrin PJ; Maldonado JH; Davis TA; June CH; Racke MK
    J Immunol; 1996 Aug; 157(4):1333-6. PubMed ID: 8759711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation.
    Cross AH; Girard TJ; Giacoletto KS; Evans RJ; Keeling RM; Lin RF; Trotter JL; Karr RW
    J Clin Invest; 1995 Jun; 95(6):2783-9. PubMed ID: 7539461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of costimulatory molecules in autoimmunity.
    Kobata T; Azuma M; Yagita H; Okumura K
    Rev Immunogenet; 2000; 2(1):74-80. PubMed ID: 11324695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-blocking agents, alone or in combination with cyclosporin A, induce antigen-specific anergy of human memory T cells.
    Yi-qun Z; Lorré K; de Boer M; Ceuppens JL
    J Immunol; 1997 May; 158(10):4734-40. PubMed ID: 9144487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.